RETRACTED ARTICLE: 5-Azacitidine for treating acute myelogenous leukemia

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Opinion on Orphan Drugs

• Publication date

  2015-09-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/21678707.2015.1089168
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Azacitidine for the treatment of relapsed and refractory AML in older patients.

  2015cited by this paper
• International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

  2015cited by this paper
• Maintenance lenalidomide in combination with 5‐azacitidine as post‐remission therapy for acute myeloid leukaemia

  2015cited by this paper
• Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.

  2015cited by this paper
• Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.

  2015cited by this paper
• Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study

  2014cited by this paper
• Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

  2014cited by this paper
• Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.

  2014cited by this paper
• Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT

  2014cited by this paper
• Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group

  2013cited by this paper
• Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)

  2013cited by this paper
• Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation

  2013cited by this paper
• A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

  2013cited by this paper
• Outcome of older patients with acute myeloid leukemia in first relapse

  2013cited by this paper
• Therapeutic Options for Patients who are not Eligible for Intensive Chemotherapy

  2013cited by this paper
• Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

  2013cited by this paper
• Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia

  2013cited by this paper
• Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients

  2013cited by this paper
• Concise drug review: azacitidine and decitabine.

  2013cited by this paper
• Azacitidine in the treatment of extramedullary relapse of AML after allogeneic hematopoietic cell transplantation

  2013cited by this paper
• Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

  2013cited by this paper
• Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.

  2013cited by this paper
• A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients

  2012cited by this paper
• Survival for older patients with acute myeloid leukemia: a population-based study

  2012cited by this paper
• Azacitidine for the treatment of patients with acute myeloid leukemia

  2012cited by this paper
• Revised international prognostic scoring system for myelodysplastic syndromes.

  2012cited by this paper
• Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine

  2012cited by this paper
• Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).

  2012cited by this paper
• Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation.

  2012cited by this paper
• Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

  2012cited by this paper
• Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia Running Title: Azacitidine plus Lenalidomide for Acute Myeloid Leukemia

  2012cited by this paper
• A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

  2012cited by this paper
• Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.

  2012cited by this paper
• Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study

  2012cited by this paper
• Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

  2012cited by this paper
• 5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.

  2011cited by this paper
• Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

  2010cited by this paper
• Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome

  2010cited by this paper
• Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

  2010cited by this paper
• In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.

  2010cited by this paper
• Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

  2010cited by this paper
• Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting

  2010cited by this paper
• Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis

  2010cited by this paper
• Azacytidine treatment after discontinuation of immunosuppressants in patients with myelodysplastic syndrome and relapse after allo-SCT at a single center

  2010cited by this paper
• Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.

  2010cited by this paper
• Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.

  2009cited by this paper
• Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

  2009cited by this paper
• Use of epigenetic modification to induce FOXP3 expression in naïve T cells.

  2009cited by this paper
• Outcomes and quality of care in acute myeloid leukemia over 40 years

  2009cited by this paper
• Low‐dose azacitidine after allogeneic stem cell transplantation for acute leukemia

  2009cited by this paper
• Leading article

  2008cited by this paper
• Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine.

  2008cited by this paper
• Allogeneic stem cell transplantation for myelodysplastic syndrome.

  2008cited by this paper
• Review Articles (434 articles)

  2008cited by this paper
• CREB/ATF-dependent T cell receptor–induced FoxP3 gene expression: a role for DNA methylation

  2007cited by this paper
• Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes

  2007cited by this paper
• Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine.

  2007cited by this paper
• A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

  2007cited by this paper
• Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

  2006cited by this paper
• Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome

  2006cited by this paper
• Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes

  2006cited by this paper
• Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

  2006cited by this paper
• Pre-Transplant 5-Azacitidine (Vidaza®) May Improve Outcome of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Myelodysplastic Syndrome (MDS).

  2006cited by this paper
• Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

  2006cited by this paper
• Decitabine improves patient outcomes in myelodysplastic syndromes

  2006cited by this paper
• Long‐term follow‐up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

  2006cited by this paper
• Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.

  2005cited by this paper
• Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes

  2005cited by this paper
• Early and Sustained Response to Azacytidine in High-Risk MDS Patients with Monosomy 7 Correlates with Increased Apoptosis and Not CDKN2B Demethylation.

  2005cited by this paper
• Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

  2004cited by this paper
• A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.

  2004cited by this paper
• Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia

  2003cited by this paper
• Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

  2002cited by this paper
• Treatment of myelodysplastic syndromes with 5-azacytidine.

  2002cited by this paper
• 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy

  2002cited by this paper
• DNA methylation patterns and epigenetic memory.

  2002cited by this paper
• Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.

  2001cited by this paper
• Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.

  2001cited by this paper
• The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997.

  1999cited by this paper
• Initiation of DNA replication at CpG islands in mammalian chromosomes

  1998cited by this paper
• International scoring system for evaluating prognosis in myelodysplastic syndromes.

  1997cited by this paper
• S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes

  1997cited by this paper
• Hypermethylation of the p15INK4B gene in myelodysplastic syndromes.

  1997cited by this paper
• The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes.

  1995cited by this paper
• Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.

  1993cited by this paper
• A predictive model for the clinical response to low dose ara‐C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia

  1992cited by this paper
• A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands.

  1992cited by this paper
• Chemotherapy and bone marrow transplantation for myelodysplastic syndromes.

  1992cited by this paper
• Evaluation of continuous infusion low‐dose 5‐azacytidine in the treatment of myelodysplastic syndromes

  1991cited by this paper
• High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines.

  1990cited by this paper
• Genetic analysis of the 5-azacytidine sensitivity of Escherichia coli K-12

  1987cited by this paper
• CpG islands in vertebrate genomes.

  1987cited by this paper
• Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience.

  1987cited by this paper
• Hemimethylated duplex DNAs prepared from 5-azacytidine-treated cells.

  1981cited by this paper
• Methylated and unmethylated DNA compartments in the sea urchin genome.

  1979cited by this paper

• Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies.

  2017cites this paper